Glaukos Corp Stock
Price
Target price
€96.00
€96.00
-1.540%
-1.5
-1.540%
-
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Glaukos Corp Stock
A loss of -1.540% shows a downward development for Glaukos Corp.
So far the community has only identified positive things for Glaukos Corp stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Glaukos Corp in the next few years
Pros
?
B****
?
C******** o* t** e**********
?
G***** c******* t* c**********
Cons
?
M***** P*******
?
S********** s********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Glaukos Corp vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Glaukos Corp | -1.540% | -6.250% | 2.632% | -35.855% | -1.015% | 103.975% | 39.286% |
| Bio-Rad Labs Inc. A | 0.040% | 2.937% | -0.460% | -24.505% | 0.582% | -40.532% | -47.276% |
| Neogen Corp. | 2.300% | 5.917% | 45.528% | -16.355% | 45.528% | - | - |
| Icu Medical Inc. | -0.790% | 2.419% | 7.627% | -18.590% | 2.419% | -29.444% | -29.050% |
News
Director Sells GKOS 15,000 Shares for $1.9 Million
Marc Stapley, a director at Glaukos Corporation (NYSE:GKOS), executed a direct sale of 15,000 shares for a transaction value of approximately $1.9 million on Jan. 22, 2026, following the exercise of
Brown Capital Sells $35 Million in Glaukos Stock After Sharp Sell-Off
Baltimore-based Brown Capital Management reported a sale of 376,359 Glaukos Corporation shares for an estimated $34.6 million in the third quarter, according to an SEC filing.
Brown Capital
Why Glaukos Stock Zoomed Almost 14% Higher on Thursday
Glaukos (NYSE: GKOS), a biotech and pharmaceutical company focused on eye disorders, was the focus of the right kind of investor attention on Thursday. Market players bid the company's stock up by